Mass Spectrometry Drug Resistance Evaluation Without Bacterial Culture

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for evaluating antimicrobial resistance of bacteria require culturing the bacteria in the presence of antimicrobial agents, which is time-consuming.

Innovation Solution

A method involving an extraction step to obtain a drug-digested enzyme from a microorganism, a mixing step with a drug, followed by mass spectrometry to detect degradation products, allowing rapid evaluation of drug resistance without culturing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If bacteria are cultured in the presence of antimicrobial agents to evaluate resistance, then the evaluation can detect metabolic changes and enzyme production, but the evaluation time becomes excessively long

Engineering Contradiction:
Improveresistance evaluation accuracyVSAvoidevaluation time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by extracting drug-digested enzymes from bacteria before exposure to the antimicrobial agent. This pre-extraction allows the enzyme to be ready for immediate reaction with the drug, eliminating the need for time-consuming culture steps while still enabling detection of drug degradation products that indicate resistance

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent extracts the drug-digested enzyme (such as β-lactamase) from the bacterial cell before the resistance evaluation process. This extraction separates the enzymatic activity from the living bacterial system, allowing direct measurement of drug degradation without requiring bacterial culture or metabolic processes, thus dramatically reducing evaluation time while maintaining detection accuracy

Inventive Principle:
Principle #2Taking out (Extraction)

2Measurement precision

If mass spectrometry is performed on metabolites using LC-MS, then metabolite detection is accurate, but the use of multiple apparatuses increases system complexity

Engineering Contradiction:
Improvemetabolite detection accuracyVSAvoidapparatus configuration
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies universality by using MALDI-MS for multiple purposes: both for identifying the causative agent of infectious disease and for evaluating antimicrobial resistance. The same mass spectrometer performs both functions by analyzing different aspects of the sample (bacterial proteins for identification, drug degradation products for resistance evaluation), eliminating the need for separate LC-MS apparatus

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent merges the functions of bacterial identification and resistance evaluation into a single integrated workflow using MALDI-MS. The system combines sample preparation, bacterial identification, and resistance assessment in one platform, reducing the number of separate apparatuses needed while maintaining measurement precision for both purposes

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables rapid determination of drug resistance by detecting drug degradation products, eliminating the need for bacterial culture and reducing evaluation time.

Implementation Method 1

β-lactamase hydrolyzes the β-lactam ring of β-lactam antimicrobial agents to inactivate them

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Implementation Method 2

the pattern of the obtained mass spectrum is collated with the mass spectrum patterns of a large number of known bacteria previously registered in a database

Methodology Applied
Scientific EffectMass spectrometry:

Data Source

PatentEP4682265A1Method for evaluating drug resistance of microorganisms
Publication Date: 2026.01.21 SHIMADZU CORP
  • EP4682265A1 patent drawingFigure 1
  • EP4682265A1 patent drawingFigure 2(a)~2(c)
  • EP4682265A1 patent drawingFigure 3(a)~3(c)

AI summary

[Summary] [Problem] To provide a method for rapidly evaluating the resistance of microorganisms such as bacteria to a drug. [Solution] The method comprises an extraction step of performing an operation to obtain an extract containing a drug-degrading enzyme that can be produced by the microorganism from a sample containing the microorganism; a mixing step of mixing the extract and a drug to obtain a mixture; an analysis step of subjecting the mixture to mass spectrometry; and an evaluation step of determining whether the microorganism is resistant to the drug by detecting the presence or absence of a peak derived from a degradation product of the drug from the mass spectrum obtained in the analysis step.